血清miR-182-5p、CFB和ADAM12在孕早期产前筛查唐氏综合征中的应用价值

Application value of serum miR-182-5p, CFB and ADAM12 detection in prenatal screening for Down's syndrome in early pregnancy

摘要

目的 探讨孕早期血清微小核糖核酸(miR)-182-5p、补体因子B(CFB)和解整合素金属蛋白酶12(ADAM12)水平在产前唐氏综合征(DS)筛查中的应用价值。方法 选取2015年1月至2022年1月雅安市人民医院收治的150例DS胎儿孕妇为DS组,另选取同期87名健康胎儿孕妇为对照组.采用实时荧光定量聚合酶链式反应检测孕早期血清miR-182-5p水平,酶联免疫吸附法检测CFB、ADAM12水平.通过多因素Logistic回归分析DS的影响因素,受试者工作特征(ROC)曲线分析孕早期血清miR-182-5p、CFB和ADAM12水平对DS的预测价值。结果 DS组年龄大于对照组,吸烟比例和CFB水平高于对照组,miR-182-5p、ADAM12水平低于对照组,差异均有统计学意义(χ²/t/Z值介于3.141~8.793之间,P＜0.05);多因素Logistic回归分析显示,年龄增加、吸烟、CFB升高为DS的独立危险因素,miR-182-5p、ADAM12升高为独立保护因素,其OR值及95%CI分别为1.122(1.012~1.243)、4.290(1.216~15.131)、1.460(1.268~1.681)、0.656(0.563~0.765)、0.996(0.994~0.998),P＜0.05;ROC曲线分析显示,孕早期血清miR-182-5p、CFB和ADAM12水平联合预测DS的曲线下面积(AUC)为0.913,大于各指标单独预测(Z值分别为5.233、4.414、4.809,P＜0.05)。结论 孕妇血清miR-182-5p、CFB和ADAM12在孕早期产前筛查唐氏综合征中具有潜在应用价值,三者联合有利于在孕早期筛查唐氏综合征.

Abstract

Objective To investigate application value of detection for serum levels of microribonucleic acid (miR)-182-5p, complement factor B (CFB) and a disintegrin and metalloprotease 12 (ADAM12) in early pregnancy in prenatal Down's syndrome (DS) screening. Methods 150 pregnant women with DS fetuses who admitted to Ya'an Municipal People's Hospital from January 2015 to January 2022 were selected as the DS group, and another 87 pregnant women with healthy fetuses in the same period were selected as the control group. Real-time fluorescence quantitative polymerase chain reaction (qPCR) was used to detect serum miR-182-5p level, and enzyme-linked immunosorbent assay (ELISA) was used to detect serum CFB and ADAM12 levels. Multifactorial Logistic regression was used to analyze influencing factors of DS and receiver operating characteristic (ROC) curves was used to analyze predictive values of serum miR-182-5p, CFB and ADAM12 levels in early pregnancy for DS. Results The pregnant women in the DS group were older than those pregnant women in the control group, their proportion of smoking and serum CFB level were higher than those in the control group, while the serum levels of miR-182-5p and ADAM12 were lower than those in the control group, and the differences were statistically significant (χ²/t/Z values ranged from 3.141 to 8.793, all P＜0.05). Multifactorial Logistic regression analysis showed that increase in age, smoking and elevated serum CFB level were independent risk factors for DS, while elevated serum miR-182-5p and ADAM12 levels were independent protective factors for DS, and their ORs (95%CIs) were 1.122 (1.012-1.243), 4.290 (1.216-15.131), 1.460 (1.268-1.681), 0.656 (0.563-0.765) and 0.996 (0.994-0.998) respectively, all P＜0.05. Receiver operating characteristic (ROC) curve analysis showed that the AUC of the combined prediction of serum miR-182-5p, CFB and ADAM12 levels in early pregnancy for DS was 0.913, which was greater than those predicted by each index alone (Z＝5.233, 4.414 and 4.809 respectively, all P＜0.05). Conclusion Detection of maternal serum miR-182-5p, CFB and ADAM12 levels has potential application values in prenatal screening for DS in early pregnancy, and the combination of all three is beneficial in screening for DS in early pregnancy.

关键词

孕早期 / 唐氏综合征 / 微小核糖核酸-182-5p / 补体因子B / 解整合素金属蛋白酶12 / 产前筛查

Key words

early pregnancy / Down's syndrome / micro ribonucleic acid-182-5p / complement factor B / a disintegrin and metalloprotease 12 / prenatal screening

参考文献

[1] 湖南省出生缺陷早期治疗技术研究课题组. 唐氏综合征儿童健康管理指南[J]. 2022, 29(8): 1011-1014.

[2] 中华医学会妇产科学分会妊娠期高血压疾病学组. 高龄妇女妊娠前、妊娠期及分娩期管理专家共识(2019)[J]. 中华妇产科杂志, 2019, 54(1): 24-26.

[3] 韩毓, 程虹, 杜就旧. 血清PAPP-A、PLGF和ADAM12检测在孕早期唐氏综合征筛查[J]. 中国计划生育学杂志, 2021, 29(6): 1213-1215, 1220.

[4] He F, Yang X. The screening of diagnostic biomarker microRNA in first-trimester maternal plasma for Down syndrome:a study protocol[J]. Medicine (Baltimore), 2022, 101(3): e28495.

[5] Veteleanu A, Pape S, Davies K, et al. Complement dysregulation and Alzheimer's disease in down syndrome[J]. Alzheimers Dement, 2023, 19(4): 1383-1392.

[6] 何建萍, 唐健, 苏虹, 等. 唐氏综合征胎盘差异miRNA表达谱分析:基于全转录组测序分析技术[J]. 南方医科大学学报, 2022, 42(3): 418-424.

[7] 蒋春艳, 王成东, 张海灵, 等. iTRAQ定量蛋白质组学技术筛选唐氏综合征孕母血清差异蛋白[J]. 哈尔滨医科大学学报, 2015, 49(6): 513-517, 520.

[8] Santoro JD, Patel L, Kammeyer R, et al. Assessment and diagnosis of Down's syndrome regression disorder:international expert consensus[J]. Front Neurol, 2022, 7(13): 940175.

[9] Zhu YN, Gan XW, Pan F, et al. Role of EZH2-mediated H3K27me3 in placental ADAM12-S expression:implications for fetoplacental growth[J]. BMC Med, 2022, 20(1): 189.

[10] 仲丽美, 王英, 李春妮, 等. 胎儿超声NT联合血清PIGF、ADAM12、uE3检测在唐氏综合征的早期预测中的价值分析[J]. 临床和实验医学杂志, 2021, 20(2): 212-215.

[11] Reza Karimzadeh M, Ehtesham N, Mortazavi D, et al. Alterations of epigenetic landscape in Down's syndrome carrying pregnancies:A systematic review of case-control studies[J]. Eur J Obstet Gynecol Reprod Biol, 2021, 8(264): 189-199.

[12] 丁凯泽, 余蕾, 黄智, 等. 唐氏综合征胎儿羊水外泌体miRNA差异表达谱分析[J]. 南方医科大学学报, 2022, 42(2): 293-299.

[13] Gai S, Sun L, Wang H, et al. Circular RNA hsa_circ_0007121 regulates proliferation,migration,invasion,and epithelial-mesenchymal transition of trophoblast cells by miR-182-5p/PGF axis in preeclampsia[J]. Open Med (Wars), 2020, 15(1): 1061-1071.

[14] Fang YN, Huang ZL, Li H, et al. Highly expressed miR-182-5p can promote preeclampsia progression by degrading RND3 and inhibiting HTR-8/Svneo cell invasion[J]. Eur Rev Med Pharmacol Sci, 2018, 22(20): 6583-6590.

[15] Lee EJ, Choi Y, Lee HJ, et al. Human neural stem cell-derived extracellular vesicles protect against Parkinson's disease pathologies[J]. J Nanobiotechnology, 2022, 20(1): 198.

[16] Soto A, Nieto-Díaz M, Reigada DB, et al. MiR-182-5p regulates nogo-A expression and promotes neurite outgrowth of hippocampal neurons in vitro[J]. Pharmaceuticals (Basel), 2022, 15(5): 529.

[17] Adams AD, Hoffmann V, Koehly L, et al. Novel insights from fetal and placental phenotyping in 3 mouse models of Down syndrome[J]. Am J Obstet Gynecol, 2021, 225(3): 296.e1-296.e13.

[18] 梁文垦, 龚蔚蔚, 侯显良, 等. 唐氏综合征神经系统发育障碍疾病模型的构建及发病机制的研究进展[J]. 广西医学, 2022, 44(6): 650-653.

[19] 冯珊珊, 魏书瑶, 何斯, 等. 补体C3与相关代谢性疾病的研究进展[J]. 西北国防医学杂志, 2021, 42(4): 254-259.

[20] Burwick RM, Feinberg BB. Complement activation and regulation in preeclampsia and hemolysis,elevated liver enzymes,and low platelet count syndrome[J]. Am J Obstet Gynecol, 2022, 226(2S): S1059-S1070.

[21] 谢竹霄, 刘磊, 王佳伟. 补体靶向治疗在神经系统自身免疫性疾病中的应用[J]. 中华神经科杂志, 2022, 55(5): 536-543.

[22] 郭楠楠, 王兴智. 补体B因子的研究进展[J]. 国际免疫学杂志, 2022, 45(1): 102-107.

[23] Belmonte B, Mangogna A, Gulino A, et al. Distinct roles of classical and lectin pathways of complement in preeclamptic placentae[J]. Front Immunol, 2022, 31(13): 882298.

[24] 邵菊, 姜智明, 林燕. 胎儿NT联合血清PAPP-A、ADAM12检测在唐氏综合征产前筛查中的临床应用[J]. 蚌埠医学院学报, 2021, 46(2): 248-251.

[25] 褚楠, 张月萍, 张斌. 高龄孕妇生育唐氏综合征患儿机制的研究进展[J]. 中华医学遗传学杂志, 2016, 33(6): 863-866.

[26] 陈正超, 刘凯波, 徐宏燕, 等. 北京市2007-2016年度出生缺陷儿母亲唐氏综合征产前血清学筛查服务利用情况及其影响因素[J]. 中国公共卫生, 2020, 36(8): 1228-1232.

基金资助

四川省卫生健康委员会科研课题(19PJ155)